CBB1007
CAS No. : 1379573-92-8
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15313 |
| M.Wt: | 534.61 |
| Formula: | C27H34N8O4 |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
CBB1007 is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma[1][2].
In Vitro:CBB1007 (0-100 μM; 30 h; F9) inhibits F9 cell growth[2].
CBB1007 (5-20 μM; 14 days; hESCs) increases lipid droplet formation in hESCs during adipogenesis[1].
CBB1007 (5-20 μM; 14 days; hESCs) reduces LSD1 and histone H3 levels while increasing H3K4me2 in human embryonic stem cells (hESCs)[1].
CBB1007 (5-20 μM; 14 days; hESCs) upregulates adipocyte marker genes PPARγ-2 and C/EBPα in hESCs[1].
CBB1007 (0.5-20 μM; 24 h; F9) activates the expression of CHRM4 and SCN3A genes[2].
CBB1007 (10 μM) significantly blocks the demethylase activity of LSD1 on mono- and di-methylated H3K4, but not tri-methylated H3K4 or di-methylated H3K9[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- CBB1007
- Cat. No.:
- HY-15313
- Quantity:
Your information is safe with us.